Valuation: Avacta Group Plc

Market Cap 29Cr 39Cr 35Cr 33Cr 55Cr 3.75TCr 56Cr 387.61Cr 155.6Cr 1.97TCr 148.07Cr 144.92Cr 6.21TCr P/E 2026 *
-8.77x
P/E 2027 * -14.6x
Enterprise Value 29Cr 39Cr 35Cr 32Cr 54Cr 3.68TCr 55Cr 381.06Cr 152.97Cr 1.94TCr 145.57Cr 142.47Cr 6.11TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day-0.82%
1 week-4.42%
1 month-15.97%
3 months-9.02%
6 months-18.24%
Current year+4.31%
1 week 60
Extreme 60
66
1 month 60
Extreme 60
70
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
152
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Director/Board Member 59 28/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Sell

Chief Financial Officer

5,00,000 0.1393%
02/09/24 Free

Chief Executive Officer

36,00,000 1.0027%
02/09/24 Exercice

Chief Financial Officer

5,00,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
-0.82%-4.42%-13.57%-55.35% 39Cr
-0.62%-1.87%+42.87%+64.15% 6.38TCr
+0.35%+3.20%+14.40%+81.76% 5.64TCr
+0.53%+1.96%+16.24%+103.35% 5.46TCr
-2.81%-4.31%+23.50%+47.83% 4.41TCr
-0.33%-1.93%+19.28%+98.80% 4.21TCr
+0.55%+2.31%+225.14%+866.21% 4.1TCr
+3.27%+47.96%+112.84%+96.58% 3.49TCr
+1.22%-1.44%+14.57%+46.95% 3.28TCr
+0.89%+20.55%-40.62%+349.24% 2.47TCr
Average +0.22%+6.34%+41.46%+169.95% 3.95TCr
Weighted average by Cap. +0.18%+5.43%+47.93%+176.44%

Financials

2026 *2027 *
Net sales - -
Net income -3.54Cr -4.74Cr -4.25Cr -3.91Cr -6.62Cr -450.53Cr -6.74Cr -47Cr -19Cr -236.99Cr -18Cr -17Cr -747.39Cr -1.4Cr -1.88Cr -1.68Cr -1.55Cr -2.62Cr -178.44Cr -2.67Cr -18Cr -7.41Cr -94Cr -7.05Cr -6.9Cr -296.02Cr
Net Debt -49.76L -66.67L -59.71L -54.92L -93.02L -63Cr -94.76L -6.55Cr -2.63Cr -33Cr -2.5Cr -2.45Cr -105.01Cr 2.08Cr 2.79Cr 2.49Cr 2.29Cr 3.89Cr 264.51Cr 3.96Cr 27Cr 11Cr 139.14Cr 10Cr 10Cr 438.79Cr
Projected Income Statement - Annual - Avacta Group Plc
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
30/26/30 GBX 60.50 -0.82% 8,33,122
29/26/29 GBX 61.00 -0.81% 7,12,499
28/26/28 GBX 61.50 -.--% 8,05,572
27/26/27 GBX 61.50 -1.60% 22,34,097
26/26/26 GBX 62.50 -1.26% 10,76,397
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Avacta Group Plc
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
0.6050GBP
Average target price
0.9175GBP
Spread / Average Target
+51.65%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avacta Group Plc
  1. Stock Market
  2. Stocks
  3. AVCT Stock